Seres Therapeutics, Inc. (NASDAQ:MCRB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday. The firm presently has a $12.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 4.71% from the stock’s previous close.
According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Other research analysts have also issued reports about the company. Canaccord Genuity set a $20.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research report on Monday, June 12th. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a research report on Friday, May 19th. Cantor Fitzgerald set a $16.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, FBR & Co restated an “outperform” rating and issued a $18.00 price target on shares of Seres Therapeutics in a research report on Monday, March 20th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Seres Therapeutics currently has an average rating of “Buy” and an average price target of $21.33.
Shares of Seres Therapeutics (NASDAQ MCRB) opened at 11.46 on Friday. Seres Therapeutics has a 12 month low of $8.05 and a 12 month high of $35.98. The stock’s 50 day moving average price is $10.29 and its 200-day moving average price is $10.15. The firm’s market capitalization is $462.87 million.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. Seres Therapeutics had a negative return on equity of 68.86% and a negative net margin of 441.10%. The business had revenue of $3.02 million for the quarter, compared to analyst estimates of $3 million. During the same period last year, the company earned ($0.50) EPS. The firm’s revenue was up 11.9% on a year-over-year basis. On average, equities research analysts predict that Seres Therapeutics will post ($2.63) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Upgrades Seres Therapeutics, Inc. (MCRB) to Buy” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/2724510/zacks-investment-research-upgrades-seres-therapeutics-inc-mcrb-to-buy.html.
A number of hedge funds have recently modified their holdings of MCRB. Geode Capital Management LLC increased its stake in shares of Seres Therapeutics by 5.8% in the first quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock valued at $1,874,000 after buying an additional 9,060 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Seres Therapeutics by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock valued at $17,645,000 after buying an additional 103,456 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of Seres Therapeutics by 14.4% in the first quarter. TIAA CREF Investment Management LLC now owns 110,076 shares of the biotechnology company’s stock valued at $1,241,000 after buying an additional 13,825 shares during the last quarter. Spark Investment Management LLC acquired a new stake in shares of Seres Therapeutics during the first quarter valued at approximately $613,000. Finally, American International Group Inc. increased its stake in shares of Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 727 shares during the last quarter. 75.51% of the stock is currently owned by institutional investors and hedge funds.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.